Kyle Kleinbeck is a scientist in the Council’s HIV and AIDS program. He studies new chemical formulations and combinations to identify the optimal safety profile for new compounds in development at the Council.
Kleinbeck contributes to the development of products that have multiple indications. While this factor increases the complexity of evaluation, it also creates products that have a high potential for offering broad-spectrum protection against sexually transmitted infections.
Before joining the Council, Kleinbeck was a formulation and process development scientist at Patheon Inc., as part of its Pharmaceutical Development Services. There he developed and optimized product formulations and manufacturing processes under cGMP guidelines.
Recipient of a National Science Foundation Fellowship and member of AAPS, Kleinbeck has authored and collaborated on many peer-reviewed articles, both prior to and during his time at the Council. Kleinbeck holds a PhD in pharmaceutical sciences and a BS in pharmacology and toxicology from the University of Wisconsin–Madison. He also studied tissue engineering at the National University of Singapore.